Article Type
Changed
Thu, 06/20/2019 - 13:10
Display Headline
An Update on the Diagnosis and Treatment of Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic, inflammatory, scarring disease that occurs most frequently along the milk lines of the body from axillae to groin, is most common in the second and third decades of life, and is rarely observed before puberty. It disproportionately affects women and is associated with a host of comorbidities and dramatically reduced quality of life. The delay from HS symptom onset to diagnosis is approximately 7 years, with drastic consequences for patient well being. Early diagnosis and treatment are of paramount importance. While several nonpharmacologic, pharmacologic, and surgical treatment modalities exist for HS, only one agent, adalimumab, has been approved by the US Food and Drug Administration for this indication. Lifestyle modifications, dietary changes, patient education, and psychosocial support are important components of HS therapy.

Click here to download PDF

Article PDF
Author and Disclosure Information

Dr. Micheletti is Assisant Professor of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

The author reports no conflicts of interest.

Issue
Cutis - 96(6)
Publications
Page Number
367, 408-409
Sections
Author and Disclosure Information

Dr. Micheletti is Assisant Professor of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

The author reports no conflicts of interest.

Author and Disclosure Information

Dr. Micheletti is Assisant Professor of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

The author reports no conflicts of interest.

Article PDF
Article PDF

Hidradenitis suppurativa (HS) is a chronic, inflammatory, scarring disease that occurs most frequently along the milk lines of the body from axillae to groin, is most common in the second and third decades of life, and is rarely observed before puberty. It disproportionately affects women and is associated with a host of comorbidities and dramatically reduced quality of life. The delay from HS symptom onset to diagnosis is approximately 7 years, with drastic consequences for patient well being. Early diagnosis and treatment are of paramount importance. While several nonpharmacologic, pharmacologic, and surgical treatment modalities exist for HS, only one agent, adalimumab, has been approved by the US Food and Drug Administration for this indication. Lifestyle modifications, dietary changes, patient education, and psychosocial support are important components of HS therapy.

Click here to download PDF

Hidradenitis suppurativa (HS) is a chronic, inflammatory, scarring disease that occurs most frequently along the milk lines of the body from axillae to groin, is most common in the second and third decades of life, and is rarely observed before puberty. It disproportionately affects women and is associated with a host of comorbidities and dramatically reduced quality of life. The delay from HS symptom onset to diagnosis is approximately 7 years, with drastic consequences for patient well being. Early diagnosis and treatment are of paramount importance. While several nonpharmacologic, pharmacologic, and surgical treatment modalities exist for HS, only one agent, adalimumab, has been approved by the US Food and Drug Administration for this indication. Lifestyle modifications, dietary changes, patient education, and psychosocial support are important components of HS therapy.

Click here to download PDF

Issue
Cutis - 96(6)
Issue
Cutis - 96(6)
Page Number
367, 408-409
Page Number
367, 408-409
Publications
Publications
Article Type
Display Headline
An Update on the Diagnosis and Treatment of Hidradenitis Suppurativa
Display Headline
An Update on the Diagnosis and Treatment of Hidradenitis Suppurativa
Sections
Citation Override
Cutis. 2015;96(suppl):7-12.
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media